AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00552331 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LISS
Description: treatment of distal femur fractures with less invasive stabilization systems
Study NCT02660242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-Pen Mini™ (glucagon injection)
Description: Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).
Study NCT02660242 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose Tabs
Description: Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).
Study NCT02660242 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basal Insulin Reduction
Description: Basal insulin reduction to 50% 5 minutes before the start of exercise.
Study NCT03027661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Inject 10 mL of 0.5% bupivacaine into cervical stroma
Study NCT03027661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: Inject 10 mL of 0.9% NaCl into cervical stroma
Study NCT02920411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatopic Treatment Cream
Description: Applied twice a day minimum.
Study NCT02920411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatopic Body lotion
Description: Applied at libitum.
Study NCT02674334 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIRS
Description: Near infrared spectroscopy (NIRS) monitor allows anesthesiologist to treat cerebral desaturations according to NIRS results while maintaining Mean Arterial Pressure (MAP) at least 60mmHG or at least 80% of baseline
Study NCT02674334 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIRS monitored not treated
Description: Near infrared spectroscopy (NIRS) monitored but anesthesiologist blinded to NIRS information and treatment is standard of care.
Study NCT03694990 — intervention group
Intervention type: OTHER
Intervention: Follow-up schedule
Description: Patients will be randomized into 1 of 3 follow-up schedules for post-operative clinic visits.
Study NCT01292161 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Silymarin
Description: Tab 210 mg, 630 mg, daily, six months.
Study NCT04569682 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LifePort transrenal artery perfusion
Description: transrenal artery perfusion group
Study NCT04569682 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifePort transrenal vein perfusion
Description: transrenal vein perfusion group
Study NCT03916952 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Six Minute Walk Test
Description: The patients walked as far as possible for 6 minutes--over two separate trials. In one trial, an examiner walked with the participant. In the second trial, the participant walked independently. A paired T test was performed to see if there was a significant difference in the distance walked or gait speed between the trials.
Study NCT01232270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: 1.1 mcg/ml for initial effect site concentration during spinal anesthesia (The effect site concentration will be changed at each subject by Dixon's up-and-down method.)
Study NCT01232270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propofol
Description: 1.1 mcg/ml for initial effect site concentration during spinal anesthesia (The effect site concentration will be changed at each subject by Dixon's up-and-down method.)
Study NCT02234609 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: modified ART class IV
Description: Carious tissue was removed with an excavator until a sound probing was obtained. Restorations were performed using a mechanically improved glass-ionomer cement for ART. The modified class IV ART restoration was inserted into the cavity using a spatula. By these restoration technique, the cavity was (i) sealed to stop further caries progression. The cavity was (ii) capped to protect the vital dentin-pulp-complex from external stimuli. The modified class IV ART was aimed at conserving the carious incisor for prospective functional use and for prolonging tooth preservation rather than at anatomical reconstruction of the tooth form for cosmetic reasons.
Study NCT02931474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesamorelin
Description: Growth Hormone-Releasing
Study NCT02931474 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00988624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon IR Tablet
Description: Pharmacokinetics of a single oral dose of 10 mg dimebon immediate release tablet will be assessed on Day 1 - 3.
Study NCT00988624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon MR1
Description: Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR1, will be assessed on Day 1 - 3.
Study NCT00988624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon MR2
Description: Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR2, will be assessed on Day 1 - 3.
Study NCT00988624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon MR3
Description: Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR3, will be assessed on Day 1 - 3.
Study NCT00988624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon MR4
Description: Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR4, will be assessed on Day 1 - 3.
Study NCT04172870 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular analysis
Description: RT- PCR
Study NCT04303988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: IV
Study NCT04303988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV
Study NCT04303988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/Carboplatin
Description: IV
Study NCT03561142 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 1- 38
Study NCT03561142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29. After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of: Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv
Study NCT03561142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep regional hyperthermia
Description: Deep regional hyperthermia to the pelvis, total time 90 min, target temperature 41-42°C. Twice weekly, up to a total of 10 sessions within d1 and d38.~Deep regional hyperthermia is offered at the centers in Tübingen and Erlangen.
Study NCT00881621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib and Capecitabine
Description: Lapatinib 1250-mg PO daily one hour before or after meals Capecitabine 1000 mg/m2 PO twice daily on days 1-14 of 21-day cycle for a total of 8 cycles
Study NCT04308577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet with added MCT
Description: The intervention is a ketogenic diet consisting of KetoCal 2,5:1 LQ MCT Multi Fibre (Nutricia), Liquigen (MCT)(Nutricia) and ketogenic meals provided by the hospital kitchen. The macronutrient composition of the ketogenic diet given approx.: Protein 11 E%, Carbohydrate 3 E%, Fat 86 E%.
Study NCT00683020 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ATSM Intervention
Description: The ATSM system is designed to promote the efficiency of a care manager by having her focus outreach phone calls to patients who, by virtue of their responses to the ATSM system, report a need for further support. The purpose of these call-backs is to have the care manager directly engage patients in setting goals and developing an action plan to improve their overall health. The care manager is trained to perform motivational interviewing, assess and overcome barriers to health communication.~For some patients, the ATSM system as described above is augmented by additional phone communications from care manager to patient, triggered by health IT derived from 2 additional data sources: SFHP pharmacy claims data and CHNSF diabetes registry. The latter combines clinical data (labs and blood pressure). Based on clinical criteria, the ATSM system will alert care manager to make additional calls to patients.
Study NCT00494975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrow band UVB phototherapy , long wave UVA phototherapy
Description: A UV irradiation cubicle (HOUVA II, National Biological Corporation, OH, U.S.A.) equipped with 24 UVA lamps (F72T12/BL9/HO UVA, National Biological Corporation, OH, U.S.A. ) and 24 UVB lamps (TL100W/01 311NB UVB, Philips Company, Eindhoven, The Netherlands).
Study NCT00494975 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Narrow band UVB phototherapy , long wave UVA phototherapy
Description: A UV irradiation cubicle (HOUVA II, National Biological Corporation, OH, U.S.A.) equipped with 24 UVA lamps (F72T12/BL9/HO UVA, National Biological Corporation, OH, U.S.A. ) and 24 UVB lamps (TL100W/01 311NB UVB, Philips Company, Eindhoven, The Netherlands).
Study NCT03703713 — intervention group
Intervention type: DRUG
Intervention: Sodium chloride
Description: Treatment with Sodium chloride
Study NCT02841709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: Capsules for oral administration containing ACT-541468 at a strength of 5 mg, 10 mg or 25 mg
Study NCT02841709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules for oral administration matching the ACT-541468 capsules
Study NCT03594123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: 2 or 3 mg tablet
Study NCT03594123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: 0.5 to 3 mg tablet
Study NCT04238767 — intervention group
Intervention type: DRUG
Intervention: Dolutegravir
Description: Eligibility to receive DTG-based ART at enrolment (i.e., initiation or offer to initiate DTG-based ART)
Study NCT02192099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel (225 mg/450 mg IV administration)
Description: Investigators began treatment in RAP-MD-05 based on the dose level to which the patient was assigned during participation in GLYX13-C-202; patients originally assigned to rapastinel 5 mg/kg received rapastinel 225 mg, and patients originally assigned to rapastinel 10 mg/kg received rapastinel 450 mg. Investigators had the option to decrease the dose level from 450 to 225 mg if a patient experienced an adverse event(s) that the investigator believed may be associated with rapastinel
Study NCT02057848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low amount of carbohydrates
Description: different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
Study NCT02057848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high amount of carbohydrates
Description: different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
Study NCT02057848 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rapid-acting carbohydrates
Description: different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
Study NCT01124851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-652
Description: See arm description for details
Study NCT01124851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See arm description for details
Study NCT03827109 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group educational activities
Description: Group educational topics include nutrition, stress, IBD and school, and disease management, and are taught by experts in each content area. s.
Study NCT03827109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group educational activities
Description: Group educational topics include nutrition, stress, IBD and school, and disease management, and are taught by experts in each content area. s.
Study NCT03827109 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IBD educational website
Description: Website with age-appropriate educational information, including information from the group educational activities.
Study NCT03827109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IBD educational website
Description: Website with age-appropriate educational information, including information from the group educational activities.
Study NCT03827109 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monthly check-in calls from program coordinator
Description: Phone calls from coordinator to encourage youth to do something fun with a friend (comparison group) or mentor (Mentoring Program). During the COVID-19 pandemic, virtual activities are encouraged. For those in the Mentoring Program, the coordinator will also ask about the mentee's relationship with the mentor.
Study NCT03827109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly check-in calls from program coordinator
Description: Phone calls from coordinator to encourage youth to do something fun with a friend (comparison group) or mentor (Mentoring Program). During the COVID-19 pandemic, virtual activities are encouraged. For those in the Mentoring Program, the coordinator will also ask about the mentee's relationship with the mentor.
Study NCT03827109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentor
Description: Mentees will be matched with a mentor for a year-long, 1:1 mentee-mentor relationship. Matching mentors and mentees is based on gender (same), age, geographical proximity, ethnicity, and interests. Mentors and mentees are expected to have weekly contact (e.g., text, phone), with in-person contact 1 - 2 times per month, one of which can be attending a group activity together. Due to the COVID-19 pandemic, a modification was approved so that all study activities can be conducted virtually, e.g., the in-person mentor-mentee monthly activity can be conducted via Skype, and group activities are live streamed
Study NCT03827109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fun group activities
Description: Program participants vote on fun group activities to participate in for support and to learn self-management skills through experiential opportunities and modeling. These are live streamed during the COVID-19 pandemic.
Study NCT03827109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent support group
Description: Parents participate in a social/support group facilitated by an Investigator while mentees and mentors are socializing during group events (virtually during the COVID-19 pandemic).
Study NCT03309956 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Holter Monitor
Description: A Holter monitor is a battery-operated portable device that measures and records your heart's electrical activity (ECG) continuously. Patients in this study will wear the monitor for 48 hours.
Study NCT03309956 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Zio Patch
Description: The Zio Patch is a small, adhesive, water-resistant single lead electrocardiographic monitoring device. Patients in this study will wear the patch for 48 hours.
Study NCT03167671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AposTherapy
Description: AposTherapy® is a home-based exercise program utilizing footwear that causes exercise with normal daily activity
Study NCT03167671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy
Description: Up to 20 sessions of traditional physical therapy
Study NCT03917771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early lymphedema detection
Description: Face-to-face consultation in Rehabilitation for early detection of lymphedema after surgery (1,6,12 months). Lower Limb measurement and care education
Study NCT03917771 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual follow-up
Description: Usual follow-up carried out in GO consultation
Study NCT01900236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Based on behavioral motivational interviewing (MI) technique
Description: In addition to receiving standard clinic care, the intervention will have a tailored, interactive agenda for each of the 4 sessions based on behavioral motivational interviewing (MI) technique. The goal of this intervention is for the participant to establish early behaviors that help him/her to arrive at scheduled medical appointments and learn to take medications as prescribed during the initial year of HIV care in order to in order to achieve viral suppression and improve overall health.
Study NCT04025879 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT04025879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days
Study NCT04025879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Specified dose on specified days
Study NCT04025879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified days
Study NCT04025879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Specified dose on specified days
Study NCT04025879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Specified dose on specified days
Study NCT04025879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Specified dose on specified days
Study NCT04025879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days
Study NCT04025879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: Specified dose on specified days
Study NCT04025879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT04025879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Specified dose on specified days
Study NCT04025879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Specified dose on specified days
Study NCT01166568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PresVIEW Scleral Implants
Description: Subjects are implanted with the PresView Scleral Spacing Implants and followed for 24 months.
Study NCT03763500 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based education
Description: A six-step Internet-based patient education.
Study NCT02313103 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: lofexidine HCl
Description: 400 micrograms
Study NCT03457909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DS-MCE
Description: During the DS-MCE examination,the capsule is allowed to travel down into gastric cardia,from where the string is slowly pulled to allow the capsule to view the esophagus retrogradely.
Study NCT03868709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penehyclidine inhalation
Description: Penehyclidine inhalation is administered by inhalation (penehyclidine hydrochloride 0.5 mg/0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients
Study NCT03868709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation
Description: Placebo inhalation is administered by inhalation (water for injection 0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygendriven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
Study NCT00215319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumbar I/F with cage and pedicle screws
Description: Surgical Titanium Mesh™ with MOSS-Miami™ Pedicle Screws
Study NCT03679741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONTROL Lens
Description: Acuvue OASYS
Study NCT03679741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEST Lens
Description: senofilcon A